Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. VivoSim Labs's Pre-Tax Income for the
three
months ended in Dec. 2025 was €-2.30 Mil. VivoSim Labs's Revenue for the
three
months ended in Dec. 2025 was €0.02 Mil. Therefore, VivoSim Labs's pretax margin for the quarter that ended in Dec. 2025 was -10,445.45%.
The historical rank and industry rank for VivoSim Labs's Pretax Margin % or its related term are showing as below:
FRA:4OR'
s Pretax Margin % Range Over the Past 10 Years
Min: -13457.8 Med: -908.37 Max: -756.05
Current: -862.68
FRA:4OR's Pretax Margin % is ranked worse than 77.3% of 947
companies
in the Biotechnology industry
Industry Median: -92.22
vs FRA:4OR: -862.68
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
VivoSim Labs Pretax Margin % Related Terms
VivoSim Labs Pretax Margin % Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs AZTR, GRI, BIXT: Pretax Margin % Comparison
For the Biotechnology subindustry, VivoSim Labs's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Pretax Margin % of -10,445.45% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #732 out of 947 companies in the Biotechnology industry, placing it in the top 77.3%.
Is VivoSim Labs' Pretax Margin % too high?
VivoSim Labs' current Pretax Margin % is -10,445.45%. Based on the distribution chart, VivoSim Labs ranks #732 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Pretax Margin % compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #732 out of 947 companies for Pretax Margin %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Pretax Margin % is -10,445.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Pretax Margin % of -10,445.45%. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Pretax Margin % is -10,445.45%. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Pretax Margin % is -10,445.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
Pretax Margin %: -10,445.45%
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
